ZeNix: Pretomanid, Bedaquiline, and Varied Doses and Durations of Linezolid in Highly Resistant TB

July 18-21, 2021; Virtual
Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.
Format: Microsoft PowerPoint (.ppt)
File Size: 231 KB
Released: July 26, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 21, 2022

Slides from CCO: Discussion of key data and recommendations for managing ART in the setting of opportunistic infections

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: March 21, 2022

Dr Milosz Parczewski, discusses the latest data on LA PrEP, HCV treatment in PWH, and treatments for MDR TB presented at CROI 2022 and their relevance to the CEE, from Clinical Care Options (CCO).

Milosz Parczewski, MD, PhD Released: March 11, 2022

Expert insight on key ART considerations for people with HIV requiring treatment for drug-susceptible tuberculosis (TB), from Clinical Care Options (CCO)

Daria Podlekareva, MD, PhD Released: March 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings